GSK
3 years ago ⋅ English ⋅ 16 min read
Newsroom
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline

For media and investors onlyIssued: 23 June 2021, London UK – LSE announcement- Sales growth more than 5% and adjusted operating profit growth more than 10% CAGR 2021-26- Sales am... Read More
GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

For media and investors onlyIssued: London, UK and San Diego, USAHalozyme’s drug delivery technology provides the opportunity to administer large volume subcutaneous injections th... Read More
GSK
3 years ago ⋅ English ⋅ 13 min read
Newsroom
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab

For media and investors only- Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalisation and risk of death in adults with mild-to-moderate CO... Read More
GSK
3 years ago ⋅ English ⋅ 8 min read
Newsroom
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

For media and investors only- EOS-448 is currently in phase I for advanced solid tumours with a randomised PD-1 combination study planned for 2022- iTeos to receive a $625 million upfro... Read More
GSK
3 years ago ⋅ English ⋅ 8 min read
Newsroom
GSK to showcase scientific advances and progress in oncology at ASCO and EHA

Company will share findings from 34 abstracts at oncology annual scientific congresses American Society of Clinical Oncology and European Hematology Association spanning priority areas... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

For media and investors only- Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circula... Read More